B. Riley reissued their buy rating on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note released on Thursday morning, MarketBeat Ratings reports. B. Riley currently has a $54.00 price target on the specialty pharmaceutical company’s stock.

Several other equities analysts have also issued reports on SUPN. Janney Montgomery Scott reiterated a hold rating and issued a $47.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Jefferies Group reiterated a buy rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Cowen reiterated a buy rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a research note on Thursday, September 21st. Piper Jaffray Companies reiterated a hold rating and issued a $41.00 price target on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $49.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $49.90.

Shares of Supernus Pharmaceuticals (SUPN) traded up $3.35 on Thursday, hitting $46.90. The stock had a trading volume of 1,233,736 shares, compared to its average volume of 523,074. Supernus Pharmaceuticals has a one year low of $23.10 and a one year high of $50.04. The company has a market cap of $2,404.19, a price-to-earnings ratio of 44.25 and a beta of 1.18.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The company’s revenue was up 41.5% on a year-over-year basis. equities analysts expect that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In related news, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total transaction of $899,600.00. Following the sale, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,461,850. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Victor Vaughn sold 55,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 145,750 shares of company stock worth $6,173,173. 6.70% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC lifted its holdings in Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares during the period. Advisor Group Inc. lifted its holdings in Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares during the period. Victory Capital Management Inc. lifted its holdings in Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 517 shares during the period. Finally, Flinton Capital Management LLC lifted its holdings in Supernus Pharmaceuticals by 88.9% during the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 2,240 shares during the period. 98.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “B. Riley Reaffirms Buy Rating for Supernus Pharmaceuticals (SUPN)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/b-riley-reaffirms-buy-rating-for-supernus-pharmaceuticals-supn/1817116.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.